Travere Therapeutics Inc (NAS:TVTX)
$ 6.285 -0.275 (-4.19%) Market Cap: 478.47 Mil Enterprise Value: 462.76 Mil PE Ratio: 0 PB Ratio: 6.48 GF Score: 58/100

Travere Therapeutics, Inc. - Special Call Transcript

Feb 02, 2021 / 01:30PM GMT
Release Date Price: $28.79 (+11.24%)
Operator

Good morning. My name is Lisa, and I will be your conference operator today. At this time, I would like to welcome everyone to the Travere Therapeutics top line interim results from Phase III DUPLEX Study of the Sparsentan in FSGS conference call. (Operator Instructions) I would like to turn the call over to Mr. Chris Cline. Please go ahead, sir.

Chris Cline
Travere Therapeutics, Inc. - SVP of IR & Corporate Communications

Great. Thank you, Lisa, and good morning, and thank you all for joining us on short notice today to talk about the top line interim results from our ongoing Phase III DUPLEX Study Sparsentan in FSGS. A copy of the press release announcing the results are available on the Investors section of our website. Today's call will be led by Chief Executive Officer, Dr. Eric Dube. Eric will be joined for the prepared remarks by Dr. Noah Rosenberg, our Chief Medical Officer; and Dr. Bill Rote, Senior Vice President of Research and Development, will join us for the Q&A session.

Before we begin, I'd like to remind everyone that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot